Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Dec;16(6):1503-1505.
doi: 10.1111/iwj.13222. Epub 2019 Sep 17.

Autologous fibroblasts for the treatment of cutaneous loxoscelism: First experience

Antonio Guglielmetti  1 , Catalina Jahr  2 , Matías Gompertz-Mattar  3
Affiliations
Case Reports

Autologous fibroblasts for the treatment of cutaneous loxoscelism: First experience

Antonio Guglielmetti et al. Int Wound J. 2019 Dec.

Abstract

Several treatments have been described for cutaneous loxoscelism (CL), but the quality of available evidence is insufficient for the elaboration of a therapeutic consensus. Dapsone has shown beneficial effects on stopping the inflammatory phenomenon and accelerating the recovery. It is recommended to start dapsone once the visceral involvement is ruled out if glucose-6-phosphate dehydrogenase levels are normal. Autologous fibroblast (AF) therapy is a novel therapy that has been successfully used in bioengineering as skin substitutes for surgical wounds and burns, diabetic and pressure ulcers, and other aesthetic purposes. Interestingly, there are no reports of AFs in CL. We present a case of CL in which the necrotic process was stabilised with dapsone, but the healing of the ulcer was not achieved. Three weekly applications of AFs 100 000/cm2 were performed on a biocompatible polymer matrix, with optimal response within 2 months. This represents the first report of AFs in CL, setting the stage for future studies.

Keywords: autologous fibroblasts; cellular therapy; dapsone; loxoscelism; skin regeneration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Before the application of AFs
Figure 2
Figure 2
First application of AFs on the biocompatible matrix
Figure 3
Figure 3
Almost complete healing 4 weeks after the first application of AFs
See this image and copyright information in PMC

References

    1. Manríquez JJ, Silva S. Cutaneous and visceral loxoscelism: a systematic review. Rev Chil Infectologia. 2009;26(5):420‐432. - PubMed
    1. Puerto CD, Saldías‐Fuentes C, Curi M, Downey C, Andino‐Navarrete R. Experience in visceral cutaneous and cutaneous loxoscelism of hospital management: clinical, evolution and therapeutic proposal. Rev Chil Infectologia. 2018;35(3):266‐275. - PubMed
    1. Cabrerizo S, Docampo PC, Cari C, et al. Loxoscelism: epidemiology and clinical aspects of an endemic pathology in the country. Arch Argent Pediatr. 2009;107(2):152‐159. - PubMed
    1. da Silva PH, da Silveira RB, Appel MH, Mangili OC, Gremski W, Veiga SS. Brown spiders and loxoscelism. Toxicon. 2004;44(7):693‐709. - PubMed
    1. Rees R, Campbell D, Rieger E, King LE. The diagnosis and treatment of brown recluse spider bites. Ann Emerg Med. 1987;16(9):945‐949. - PubMed

Publication types